Clinical Trial Update: Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC [Phase 1, Phase 2]

View source ↗

Summary

An update on a Phase I dose-escalation study of fractionated 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (Phase I/II), with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (Lutetium-177-PSMA-617) (Lutetium-177-PSMA-617)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-12-13